KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Non-cash Items: 2009-2024

  • Acadia Pharmaceuticals' Non-cash Items fell 92.31% to $7.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $7.0 million, marking a year-over-year decrease of 92.31%. This contributed to the annual value of $7.0 million for FY2024, which is 92.31% down from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Non-cash Items of $7.0 million as of Q4 2024, which was down 92.31% from $91.0 million recorded in Q4 2023.
  • Acadia Pharmaceuticals' 5-year Non-cash Items high stood at $379.2 million for Q4 2020, and its period low was $1.1 million during Q4 2022.
  • Its 3-year average for Non-cash Items is $33.0 million, with a median of $7.0 million in 2024.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Non-cash Items crashed by 95.67% in 2021, and later surged by 8,546.58% in 2023.
  • Acadia Pharmaceuticals' Non-cash Items (Quarterly) stood at $379.2 million in 2020, then slumped by 95.67% to $16.4 million in 2021, then plummeted by 93.59% to $1.1 million in 2022, then spiked by 8,546.58% to $91.0 million in 2023, then crashed by 92.31% to $7.0 million in 2024.
  • Its last three reported values are $7.0 million in Q4 2024, $91.0 million for Q4 2023, and $1.1 million during Q4 2022.